Health Care

EVP & CSO Lennox Abigail’s July RSU purchase shows Perrigo leadership’s confidence, boosting long‑term upside and reinforcing investor trust.

TruBridge’s insider sales at $26.25 mark the final chapter of its IKS Health takeover, offering investors a clear exit while highlighting executive confidence in the merger’s value.

Insider buying spree at Mesoblast shows CFO and execs expect a rise—backed by new CAR‑T therapy data and strong social buzz, but still a volatile, loss‑making biotech.

Workman Kurt’s July sell of 21,001 Owlet shares signals routine portfolio rebalancing, not a warning—investors can still trust the CEO’s long‑term stake in pulse‑oximetry baby monitors.

Insider buys at Personalis show CEO Hall Christopher M’s confidence in its 50%+ rally, yet investors should watch FDA milestones before betting big.

Holgerson’s steady stake in Cigna, amid high buzz and negative sentiment, signals confidence in the insurer’s long‑term strategy and strong fundamentals.

Insider sales at Abeona signal tax‑planning, not panic—yet investors should watch for pipeline wins and liquidity shifts.

Insider buys at Neurocrine reveal confidence in its neuro‑psychiatric pipeline and upside potential—see how the CEO’s 10b5‑1 trades signal long‑term optimism.

Insight: Borgeson Blake’s July 7 insider sale of 40,000 Recursion shares—priced at $3.96—signals cautious liquidity amid rising buzz, urging investors to watch short‑term volatility and the company’s AI‑driven drug pipeline for long‑term confidence.

Insider trading at Immunome shows steady, rule‑based moves—buy low, sell high—hinting at confidence while highlighting a long‑term upside amid current valuation gaps.